Insights from structural analysis of cFMS/inhibitor complexes: common interactions via three structurally dissimilar scaffolds.
A small-molecule drug discovery effort can benefit from having several chemical series. Where multiple series are not available, it is often the goal of a project to find novel scaffolds. Structural studies of ligand/protein complexes provide important information on the interactions driving binding. By generalizing these, it is possible to find molecules lacking in similarity in their connectivity yet retaining the ability to interact with the same target protein. Our studies on inhibitors of the cFMS tyrosine kinase provide a dramatic example of three different chemical series that make the same key interactions with the target protein. Collectively, these structural data provide a striking example of the pharmacophore hypothesis at work. In addition, they should prompt one to employ a broad approach when attempting scaffold hopping or any search for a novel series. It is clear that molecules that bind with similar interactions to a target need not possess 2-dimensional molecular similarity.